Cover ImageSALE
市場調查報告書

卵巢癌的基因治療市場 - 開發平台分析報告

Gene Therapy for Ovarian Cancer- A Pipeline Analysis Report

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 599683
出版日期 內容資訊 英文 73 Pages
訂單完成後即時交付
價格
Back to Top
卵巢癌的基因治療市場 - 開發平台分析報告 Gene Therapy for Ovarian Cancer- A Pipeline Analysis Report
出版日期: 2018年02月27日 內容資訊: 英文 73 Pages
簡介

本報告提供各種發展階段中包含分子的卵巢癌的基因治療的臨床試驗形勢的詳細洞察。還有依據給藥途徑和標的等各種區隔的開發平台分子的治療評估相關全面的資訊

本報告處理的項目

  • 卵巢癌的各種發展階段的基因治療分子
  • 現在從事卵巢癌的基因治療分子的開發的企業
  • 恰當的推論對於中止/惰性分子的洞察
  • 批准各地區的藥品的主要法規當局
  • 各活性分子詳細的分析

目錄

第1章 摘要整理

第2章 調查範圍

第3章 調查方法

第4章 卵巢癌的基因治療:洞察

  • 簡介

第5章 主要法規當局

  • 美國
  • 歐洲
  • 日本
  • 澳洲
  • 中國

第6章 開發平台形勢

第7章 比較分析

  • 中期分子(階段II及I / II)
  • 初期階段分子(階段I)
  • 惰性分子

第8章 表示分析

第9章 治療評估(ROA基礎)

第10章 治療評估(各標的)

第11章 主要企業

  • 活躍的企業:範疇與參數
  • 附錄
  • 簡稱清單

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: IRTNTR20288

This pipeline analysis report provides detailed insights into the clinical trials landscape of the gene therapy for ovarian cancer including molecules at various development stages. The report also offers comprehensive information about the therapeutic assessment of the pipeline molecules based on various segmentations such as route of administration and target.

Key questions answered in the report include:

  • What are the gene therapy molecules in the various development stages for ovarian cancer?
  • What are the companies that are currently involved in the development of gene therapy molecules for ovarian cancer?
  • Insight into discontinued/inactive molecules with appropriate reasoning?
  • What are the major regulatory authorities approving drugs in various regions?
  • Detailed profiling of each active molecule.

Table of Contents

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: GENE THERAPY FOR OVARIAN CANCER: AN INSIGHT

  • Introduction

PART 05: MAJOR REGULATORY AUTHORITIES

  • US
  • Europe
  • Japan
  • Australia
  • China

PART 06: PIPELINE LANDSCAPE

PART 07: COMPARATIVE ANALYSIS

  • Mid-stage molecules (Phase II and I/II), 2017
  • Early-stage molecules (Phase I), 2017
  • Inactive molecules, 2017

PART 08: INDICATION ANALYSIS

PART 09: THERAPEUTIC ASSESSMENT (ROA BASED)

PART 10: THERAPEUTIC ASSESSMENT (BY TARGET)

PART 11: KEY COMPANIES

  • Active companies: Category and parameters
  • APPENDIX
  • List of abbreviations

List of Exhibits

  • Exhibit 01: Drug approval process by US FDA
  • Exhibit 02: Pipeline landscape
  • Exhibit 03: Pipeline molecules by vendors
  • Exhibit 04: Pipeline molecules by numbers
  • Exhibit 05: Pipeline molecules by percentage
  • Exhibit 06: Overview: p53 gene therapy
  • Exhibit 07: Clinical trials description of p53 gene
  • Exhibit 08: Overview: Ofranergene obadenovec
  • Exhibit 09: Clinical trials description of Ofranergene obadenovec
  • Exhibit 10: Overview: GEN-1
  • Exhibit 11: Clinical trials description of GEN-1
  • Exhibit 12: Overview: LOAd703
  • Exhibit 13: Clinical trials description of LOAd703
  • Exhibit 14: Overview: ONCOS-102
  • Exhibit 15: Clinical trials description of ONCOS-102
  • Exhibit 16: Overview: Aglatimagene besadenovec
  • Exhibit 17: Clinical trials description of Aglatimagene besadenovec
  • Exhibit 18: Overview: TBI-1301
  • Exhibit 19: Clinical trials description of TBI-1301
  • Exhibit 20: Overview: BC-819
  • Exhibit 21: Clinical trials description of BC-819
  • Exhibit 22: Overview: MetXia
  • Exhibit 23: Overview: Gene therapy for ovarian cancer
  • Exhibit 24: Analysis by type of ovarian cancer
  • Exhibit 25: Overview of indication
  • Exhibit 26: Assessment by RoA
  • Exhibit 27: Segmentation of pipeline by stage and RoA
  • Exhibit 28: Assessment by target
  • Exhibit 29: Vendor landscape
  • Exhibit 30: Segmentation of companies
  • Exhibit 31: Overview: Advantagene, 2017
  • Exhibit 32: Overview: CELSION, 2017
  • Exhibit 33: Overview: Lokon Pharma, 2017
  • Exhibit 34: Overview: SiBiono GeneTech, 2017
  • Exhibit 35: Overview: Takara Bio, 2017
  • Exhibit 36: Overview: Targovax, 2017
  • Exhibit 37: Overview: Vascular Biogencies, 2017
Back to Top